TME Current Deferred Revenue from 2010 to 2026
| ALTME Stock | 0.08 0 1.47% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 402.3 K | Current Value 700.3 K | Quarterly Volatility 395.5 K |
Check TME Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TME Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.5 K, Interest Expense of 549.5 K or Selling General Administrative of 1.6 M, as well as many indicators such as Price To Sales Ratio of 92.3, Dividend Yield of 0.0 or PTB Ratio of 1.2. TME financial statements analysis is a perfect complement when working with TME Pharma Valuation or Volatility modules.
TME | Current Deferred Revenue |
Evaluating TME Pharma's Current Deferred Revenue across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into TME Pharma NV's fundamental strength.
Latest TME Pharma's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of TME Pharma NV over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. TME Pharma's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TME Pharma's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
TME Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 716,386 | |
| Geometric Mean | 650,348 | |
| Coefficient Of Variation | 55.21 | |
| Mean Deviation | 254,551 | |
| Median | 564,000 | |
| Standard Deviation | 395,545 | |
| Sample Variance | 156.5B | |
| Range | 1.6M | |
| R-Value | 0.06 | |
| Mean Square Error | 166.3B | |
| R-Squared | 0 | |
| Significance | 0.82 | |
| Slope | 4,630 | |
| Total Sum of Squares | 2.5T |
TME Current Deferred Revenue History
About TME Pharma Financial Statements
TME Pharma shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although TME Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in TME Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on TME Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 402.3 K | 700.3 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for TME Stock Analysis
When running TME Pharma's price analysis, check to measure TME Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TME Pharma is operating at the current time. Most of TME Pharma's value examination focuses on studying past and present price action to predict the probability of TME Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TME Pharma's price. Additionally, you may evaluate how the addition of TME Pharma to your portfolios can decrease your overall portfolio volatility.